78360
document
[ The somatostatin infusion test for the evaluation of glucose utilization in bezafibrate medication ] . The utilisation of blood glucose may be used for definition of insulin resistance in type II diabetes mellitus . To evaluate this possibility we adapted an infusion test of somatostatin in 10 normal persons ( age 26 +/- 3 years , relative body weight 26 +/- 10 % according to Broca ) in a randomized cross-over therapy with bezafibrate ( 3 X 200 mg/die ) . As the coefficient of variation ( VC ) of measured blood glucose continuously increased the best time of a steady state was between 90 and 130 min after beginning the infusion ( mean VC 8.9 % ) . While insulin remained nearly constant ( 41 ( 45 ; 38 ) microU/ml ) blood glucose dropped by about 14 % and reached a steady state of 89 ( 134 ; 45 ) mg/dl . During the therapy of bezafibrate blood glucose was significantly decreased by 36 % 130 min after beginning the infusion . Although the effect was not significant during the whole time of the steady state it became evident by a negative correlation with lactate ( r = -0.687 ) and pyruvate ( r = -0.843 ) . A correlation with a concomitant decrease of triglyceride and cholesterol also induced by bezafibrate could not be proven . The results show that the infusion test of somatostatin is fitted to measure a steady state of blood glucose and insulin and that it is possible by this technique to quantify a changed utilisation of blood glucose induced by specific therapy .
78361
Intervention_Physical
somatostatin infusion test
78362
Intervention_Pharmacological
bezafibrate medication
78363
Intervention_Pharmacological
blood glucose
78364
Intervention_Pharmacological
infusion test of somatostatin
78365
Intervention_Pharmacological
bezafibrate
78366
Intervention_Pharmacological
bezafibrate
78367
Intervention_Pharmacological
bezafibrate
78368
Intervention_Pharmacological
infusion test of somatostatin
78369
Outcome_Physical
glucose utilization
78370
Outcome_Physical
blood glucose
78371
Outcome_Physical
blood glucose
78372
Outcome_Physical
insulin
78373
Outcome_Physical
blood glucose
78374
Outcome_Physical
blood glucose
78375
Outcome_Physical
triglyceride
78376
Outcome_Physical
cholesterol
78377
Outcome_Physical
blood glucose
78378
Outcome_Physical
insulin
78379
Participant_Condition
type II diabetes mellitus .